<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<html xmlns:n1="urn:hl7-org:v3" xmlns:in="urn:lantana-com:inline-variable-data" xmlns:sdtc="urn:hl7-org:sdtc"><head>
<meta charset="utf-8"><!-- Do NOT edit this HTML directly: it was generated via an XSLT transformation from a CDA Release 2 XML document. --><title>Progress note - [REDACTED]</title><style type="text/css">
body {
  color: #003366;
  background-color: #FFFFFF;
  font-family: Verdana, Tahoma, sans-serif;
  font-size: 14px;
}

a {
  color: #003366;
  background-color: #FFFFFF;
}

h1 {
  font-size: 20px;
  font-weight: bold;
}

h2 {
  font-size: 18px;
  font-weight: bold;
}

h3 {
  font-size: 14px;
  font-weight: bold;
}

h4 {
  font-size: 14px;
  font-weight: bold;
}


table {
  width: 100%;
}

th {
  background-color: #ffd700;
}

td {
  padding: 0.1cm 0.2cm;
  vertical-align: top;
  background-color: #ffffcc;
}

.h1center {
  font-size: 20px;
  font-weight: bold;
  text-align: center;
  width: 80%;
}

.header_table{
  border: 1pt inset #00008b;
}

.td_label{
  font-weight: bold;
  color: white;
}

.content_span{
 font-family: Verdana, Tahoma, sans-serif;
 display: inline;
 white-space: pre-line;
}

.td_header_role_name{
  width: 20%;
  background-color: #3399ff;
}

.td_header_role_value{
  width: 80%;
  background-color: #ccccff;
}

.Bold{
  font-weight: bold;
}

.Italics{
  font-style: italic;
}

.Underline{
  text-decoration:underline;
}

.internal_format
{
	list-style: none;
	list-style-position:outside;
	margin:0;
	padding:0;
	border:0;
	border-collapse: collapse;
}
          </style></head><body>
<h2><a name="toc">Table of Contents</a></h2><ul><li><a href="#id1">ALLERGIES</a></li><li><a href="#id2">RESULTS</a></li><li><a href="#id3">REASON FOR VISIT</a></li><li><a href="#id4">MEDICATIONS</a></li><li><a href="#id5">IMMUNIZATIONS</a></li><li><a href="#id6">PROBLEMS</a></li><li><a href="#id7">VITAL SIGNS</a></li><li><a href="#id8">PROCEDURES</a></li><li><a href="#id9">Encounters</a></li><li><a href="#id10">ASSESSMENTS</a></li><li><a href="#id11">PLAN OF TREATMENT</a></li><li><a href="#id12">Progress Notes</a></li></ul><hr align="left" color="teal" size="2"/><h3><a name="id1" href="#toc">ALLERGIES</a></h3><div><span class="content_span">No Known Allergies</span></div><h3><a name="id2" href="#toc">RESULTS</a></h3><div><table width="100%" border="1"><thead><tr><th>Component</th><th>Value</th><th>Reference Range</th><th>Notes</th></tr></thead><tbody><tr><td colspan="4"><span class="content_span">Thyroid Profile with tsh</span><br/>Reviewed date:[REDACTED] 10:26:55 AM<br/>Interpretation:<br/>Performing Lab:LabCorp [REDACTED], [REDACTED][REDACTED][REDACTED], Phone - [REDACTED], Director - MDEskue<br/>Notes/Report:</td></tr><tr><td ID="result1_attr1">TSH</td><td>6.170</td><td>0.450-4.500 uIU/mL</td><td/></tr><tr><td ID="result1_attr2">Thyroxine (T4)</td><td>5.8</td><td>4.5-12.0 ug/dL</td><td/></tr><tr><td ID="result1_attr3">T3 Uptake</td><td>26</td><td>24-39 %</td><td/></tr><tr><td ID="result1_attr4">Free Thyroxine Index</td><td>1.5</td><td>1.2-4.9</td><td/></tr></tbody></table></div><h3><a name="id3" href="#toc">REASON FOR VISIT</a></h3><div>DMII, DLD, HTN, Hypothyroidism, BPH, CKD V, Gout, GERD, Depression</div><h3><a name="id4" href="#toc">MEDICATIONS</a></h3><div><table width="100%" border="1"><thead><tr><th>Medication</th><th>SIG (Take, Route, Frequency, Duration)</th><th>Notes</th><th>Start Date</th><th>End Date</th><th>Status</th></tr></thead><tbody><tr><td ID="medication1">Fenofibrate 145 MG</td><td ID="instruction1">1 tablet Orally Once a day for 90 days</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication2">Levothyroxine Sodium 75 MCG</td><td ID="instruction2">1 tablet in the morning on an empty stomach Orally Once a day for 90 days</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication3">Tresiba FlexTouch 100 UNIT/ML</td><td ID="instruction3">6 units Subcutaneous daily for 30 day(s)</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication4">NovoLOG FlexPen 100 UNIT/ML</td><td ID="instruction4">3 units Subcutaneous daily for 30 day(s)</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication5">Penlac 8 %</td><td ID="instruction5">1 application to affected area Externally Once a day for 30 days</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication6">Finasteride 5 MG</td><td ID="instruction6">1 tablet Orally Once a day for 90 day(s)</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication7">Tradjenta 5 MG</td><td ID="instruction7">1 tablet Orally Once a day for 90 days</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication8">Atorvastatin Calcium 40 MG</td><td ID="instruction8">1 tablet Orally Once a day for 90 days</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication9">Docusate Sodium 100 MG</td><td ID="instruction9">1 capsule as needed Orally Once a day for 30 day(s)</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication10">Tamsulosin HCl 0.4 MG</td><td ID="instruction10">1 capsule Orally Once a day for 90 days</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication11">Famotidine 20 MG</td><td ID="instruction11">1 tablet at bedtime as needed Orally Once a day</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication12">Allopurinol 100 MG</td><td ID="instruction12">1 tablet Orally Once a day for 30 day(s)</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication13">Labetalol HCl 200 MG</td><td ID="instruction13">1 tablet Orally Twice a day</td><td/><td/><td/><td>Active</td></tr><tr><td ID="medication14">traMADol-Acetaminophen 37.5-325 MG</td><td ID="instruction14">1 tab Orally every 12 hrs for 30 days</td><td/><td/><td/><td>Active</td></tr></tbody></table></div><h3><a name="id5" href="#toc">IMMUNIZATIONS</a></h3><div><table width="100%" border="1"><thead><tr><th>Vaccine</th><th>Route</th><th>Administration Date</th><th>Status</th><th>Comments</th></tr></thead><tbody><tr><td ID="immunization1">Influenza Vaccine</td><td>Unknown</td><td>[REDACTED]</td><td>Refused</td><td ID="immunization1notes">FLU ADMINISTERED ON 09/2023</td></tr></tbody></table></div><h3><a name="id6" href="#toc">PROBLEMS</a></h3><div><table width="100%" border="1"><thead><tr><th>Problem Type</th><th>ICD Code</th><th>Onset Dates</th><th>Problem Status</th><th>W/U Status</th><th>Risk</th><th>SNOMED Code</th><th>Notes</th></tr></thead><tbody><tr><td>Problem</td><td ID="Problem1">Major depressive disorder, recurrent, in full remission (F33.42)</td><td/><td>Active</td><td>confirmed</td><td/><td>Recurrent major depression in full remission (46244001)</td><td/></tr></tbody></table></div><h3><a name="id7" href="#toc">VITAL SIGNS</a></h3><div><table width="100%" border="1"><tbody><tr><th ID="vital1">Temperature</th><td>98.2 degrees Fahrenheit</td><td>[REDACTED]</td></tr><tr><th ID="vital2">Blood pressure systolic</th><td>121 mm Hg</td><td>[REDACTED]</td></tr><tr><th ID="vital3">Blood pressure diastolic</th><td>65 mm Hg</td><td>[REDACTED]</td></tr><tr><th ID="vital4">Heart Rate</th><td>94 /min</td><td>[REDACTED]</td></tr><tr><th ID="vital5">Height</th><td>66 in</td><td>[REDACTED]</td></tr><tr><th ID="vital6">Weight</th><td>209.2 lbs</td><td>[REDACTED]</td></tr><tr><th ID="vital7">BMI</th><td>33.76 kg/m2</td><td>[REDACTED]</td></tr><tr><td colspan="3"><span class="content_span">RBS 197
DONE BY [REDACTED] [REDACTED]/MA</span></td></tr></tbody></table></div><h3><a name="id8" href="#toc">PROCEDURES</a></h3><div><table width="100%" border="1"><thead><tr><th>Procedure</th><th>Date Ordered</th><th>Date Performed</th><th>Result</th><th>Body Site</th></tr></thead><tbody><tr><td ID="procedure1">PHQ9</td><td>[REDACTED]</td><td/><td>N/A</td><td/></tr></tbody></table></div><h3><a name="id9" href="#toc">Encounters</a></h3><div><table width="100%" border="1"><thead><tr><th>Encounter</th><th>Location</th><th>Date</th><th>Provider</th><th>Diagnosis</th></tr></thead><tbody><tr><td>[REDACTED] MD PA</td><td>[REDACTED][REDACTED]</td><td>[REDACTED]</td><td>[REDACTED]</td><td>Type 2 diabetes mellitus with hyperglycemia E11.65 ; Mixed hyperlipidemia E78.2 ; Essential (primary) hypertension I10 ; Other specified hypothyroidism E03.8 ; Benign prostatic hyperplasia without lower urinary tract symptoms N40.0 ; Chronic kidney disease, stage 5 N18.5 ; Gout, unspecified M10.9 ; Gastro-esophageal reflux disease without esophagitis K21.9 ; Major depressive disorder, recurrent, in full remission F33.42 ; Alcohol dependence, in remission F10.21 ; Primary generalized (osteo)arthritis M15.0 ; Other constipation K59.09 ; Type 2 diabetes mellitus with diabetic chronic kidney disease E11.22 ; Type 2 diabetes mellitus with other specified complication E11.69 ; Type 2 diabetes mellitus with diabetic nephropathy E11.21 ; Immunodeficiency due to conditions classified elsewhere D84.81 ; Secondary hyperparathyroidism of renal origin N25.81 ; Type 2 diabetes mellitus with other skin complications E11.628 ; Tinea unguium B35.1 ; Long term (current) use of insulin Z79.4 ; Opioid dependence, uncomplicated F11.20 and Body mass index (BMI) 33.0-33.9, adult Z68.33</td></tr></tbody></table></div><h3><a name="id10" href="#toc">ASSESSMENTS</a></h3><div><table width="100%" border="1"><thead><tr><th>Encounter Date</th><th>Diagnosis</th><th>Assessment Notes</th><th>Treatment Notes</th><th>Treatment Clinical Notes</th></tr></thead><tbody><tr><td ID="ref1">[REDACTED]</td><td>Type 2 diabetes mellitus with hyperglycemia (ICD-10 - E11.65)</td><td/><td> A1c 6.8 ([REDACTED])</td><td/></tr><tr><td ID="ref2">[REDACTED]</td><td>Mixed hyperlipidemia (ICD-10 - E78.2)</td><td/><td/><td/></tr><tr><td ID="ref3">[REDACTED]</td><td>Essential (primary) hypertension (ICD-10 - I10)</td><td/><td/><td/></tr><tr><td ID="ref4">[REDACTED]</td><td>Other specified hypothyroidism (ICD-10 - E03.8)</td><td/><td/><td/></tr><tr><td ID="ref5">[REDACTED]</td><td>Benign prostatic hyperplasia without lower urinary tract symptoms (ICD-10 - N40.0)</td><td/><td/><td/></tr><tr><td ID="ref6">[REDACTED]</td><td>Chronic kidney disease, stage 5 (ICD-10 - N18.5)</td><td/><td><p>Continue with ARBs, advised on importance of aggressive BP control, avoidance of NSAIDs</p><p>eGFR: 15 ([REDACTED])</p><p>PTH: 199 ([REDACTED])</p></td><td/></tr><tr><td ID="ref7">[REDACTED]</td><td>Gout, unspecified (ICD-10 - M10.9)</td><td/><td/><td/></tr><tr><td ID="ref8">[REDACTED]</td><td>Gastro-esophageal reflux disease without esophagitis (ICD-10 - K21.9)</td><td/><td/><td/></tr><tr><td ID="ref9">[REDACTED]</td><td>Major depressive disorder, recurrent, in full remission (ICD-10 - F33.42)</td><td/><td> PHQ9 : 0 ([REDACTED]) Currenlty asymptomatic, will monitor. </td><td/></tr><tr><td ID="ref10">[REDACTED]</td><td>Alcohol dependence, in remission (ICD-10 - F10.21)</td><td/><td>Advised patient on importance of continued abstinence.</td><td/></tr><tr><td ID="ref11">[REDACTED]</td><td>Primary generalized (osteo)arthritis (ICD-10 - M15.0)</td><td/><td/><td/></tr><tr><td ID="ref12">[REDACTED]</td><td>Other constipation (ICD-10 - K59.09)</td><td/><td/><td/></tr><tr><td ID="ref13">[REDACTED]</td><td>Type 2 diabetes mellitus with diabetic chronic kidney disease (ICD-10 - E11.22)</td><td/><td><p>Advised importance of maintaining BP &lt;130/80, FBS &lt;130, and RBS &lt;200 </p><p>Advised on importance of compliance with all medications and report any side effects</p></td><td/></tr><tr><td ID="ref14">[REDACTED]</td><td>Type 2 diabetes mellitus with other specified complication (ICD-10 - E11.69)</td><td/><td>Associated with mixed hyperlipidemia</td><td/></tr><tr><td ID="ref15">[REDACTED]</td><td>Type 2 diabetes mellitus with diabetic nephropathy (ICD-10 - E11.21)</td><td/><td><p>Abnormal urine micro, continue with aggressive BP and glucose control</p><p>ACR: 114 ([REDACTED])</p></td><td/></tr><tr><td ID="ref16">[REDACTED]</td><td>Immunodeficiency due to conditions classified elsewhere (ICD-10 - D84.81)</td><td/><td>Secondary to DM type 2</td><td/></tr><tr><td ID="ref17">[REDACTED]</td><td>Secondary hyperparathyroidism of renal origin (ICD-10 - N25.81)</td><td/><td><p>Secondary hyperparathyroidism due to history of chronic kidney disease</p><p>PTH level: 199 ([REDACTED])</p></td><td/></tr><tr><td ID="ref18">[REDACTED]</td><td>Type 2 diabetes mellitus with other skin complications (ICD-10 - E11.628)</td><td/><td>Patient with physical findings of onychomycotic toenails</td><td/></tr><tr><td ID="ref19">[REDACTED]</td><td>Tinea unguium (ICD-10 - B35.1)</td><td/><td/><td/></tr><tr><td ID="ref20">[REDACTED]</td><td>Long term (current) use of insulin (ICD-10 - Z79.4)</td><td/><td><p>Currently on Insulin: Tresiba FlexTouch and NovoLog FlexPen</p><p>Patient was offered to have nursing assistance to educate him on proper administration of insulin for 1 month. Patient refused, requesting permanent home health for insulin administration.</p></td><td/></tr><tr><td ID="ref21">[REDACTED]</td><td>Opioid dependence, uncomplicated (ICD-10 - F11.20)</td><td/><td> Currently on Tramadol. Have advised patient on importance of decreasing frequency and/or discontinuing medication but patient refuses at this time. Will continue to actively address. </td><td/></tr><tr><td ID="ref22">[REDACTED]</td><td>Body mass index (BMI) 33.0-33.9, adult (ICD-10 - Z68.33)</td><td/><td/><td/></tr><tr><td ID="ref23">[REDACTED]</td><td>Other</td><td/><td>Patient seen and examined under direct supervision of [REDACTED].  PMP was reviewed prior to dispensing medications. </td><td/></tr></tbody></table></div><h3><a name="id11" href="#toc">PLAN OF TREATMENT</a></h3><div><span class="content_span">Medication</span><table width="100%" border="1"><thead><tr><th>Medication Name</th><th>Sig</th><th>Start Date</th><th>Stop Date</th><th>Notes</th></tr></thead><tbody><tr><td ID="potMeds1">Fenofibrate 145 MG</td><td>1 tablet Orally Once a day for 90 days</td><td/><td/><td/></tr><tr><td ID="potMeds2">Levothyroxine Sodium 75 MCG</td><td>1 tablet in the morning on an empty stomach Orally Once a day for 90 days</td><td/><td/><td/></tr><tr><td ID="potMeds3">Tresiba FlexTouch 100 UNIT/ML</td><td>6 units Subcutaneous daily for 30 day(s)</td><td/><td/><td/></tr><tr><td ID="potMeds4">NovoLOG FlexPen 100 UNIT/ML</td><td>3 units Subcutaneous daily for 30 day(s)</td><td/><td/><td/></tr><tr><td ID="potMeds5">Penlac 8 %</td><td>1 application to affected area Externally Once a day for 30 days</td><td/><td/><td/></tr><tr><td ID="potMeds6">Finasteride 5 MG</td><td>1 tablet Orally Once a day for 90 day(s)</td><td/><td/><td/></tr><tr><td ID="potMeds7">Tradjenta 5 MG</td><td>1 tablet Orally Once a day for 90 days</td><td/><td/><td/></tr><tr><td ID="potMeds8">Atorvastatin Calcium 40 MG</td><td>1 tablet Orally Once a day for 90 days</td><td/><td/><td/></tr><tr><td ID="potMeds9">Docusate Sodium 100 MG</td><td>1 capsule as needed Orally Once a day for 30 day(s)</td><td/><td/><td/></tr><tr><td ID="potMeds10">Tamsulosin HCl 0.4 MG</td><td>1 capsule Orally Once a day for 90 days</td><td/><td/><td/></tr><tr><td ID="potMeds11">Famotidine 20 MG</td><td>1 tablet at bedtime as needed Orally Once a day</td><td/><td/><td/></tr><tr><td ID="potMeds12">Allopurinol 100 MG</td><td>1 tablet Orally Once a day for 30 day(s)</td><td/><td/><td/></tr><tr><td ID="potMeds13">Labetalol HCl 200 MG</td><td>1 tablet Orally Twice a day</td><td/><td/><td/></tr><tr><td ID="potMeds14">traMADol-Acetaminophen 37.5-325 MG</td><td>1 tab Orally every 12 hrs for 30 days</td><td/><td/><td/></tr></tbody></table><span class="content_span">Treatment Notes</span><table width="100%" border="1"><thead><tr><th>Assessment</th><th>Notes</th></tr></thead><tbody><tr><td ID="instructionpot1">Type 2 diabetes mellitus with hyperglycemia</td><td> A1c 6.8 ([REDACTED])</td></tr><tr><td ID="instructionpot2">Chronic kidney disease, stage 5</td><td><p>Continue with ARBs, advised on importance of aggressive BP control, avoidance of NSAIDs</p><p>eGFR: 15 ([REDACTED])</p><p>PTH: 199 ([REDACTED])</p></td></tr><tr><td ID="instructionpot3">Major depressive disorder, recurrent, in full remission</td><td> PHQ9 : 0 ([REDACTED]) Currenlty asymptomatic, will monitor. </td></tr><tr><td ID="instructionpot4">Alcohol dependence, in remission</td><td>Advised patient on importance of continued abstinence.</td></tr><tr><td ID="instructionpot5">Type 2 diabetes mellitus with diabetic chronic kidney disease</td><td><p>Advised importance of maintaining BP &lt;130/80, FBS &lt;130, and RBS &lt;200 </p><p>Advised on importance of compliance with all medications and report any side effects</p></td></tr><tr><td ID="instructionpot6">Type 2 diabetes mellitus with other specified complication</td><td>Associated with mixed hyperlipidemia</td></tr><tr><td ID="instructionpot7">Type 2 diabetes mellitus with diabetic nephropathy</td><td><p>Abnormal urine micro, continue with aggressive BP and glucose control</p><p>ACR: 114 ([REDACTED])</p></td></tr><tr><td ID="instructionpot8">Immunodeficiency due to conditions classified elsewhere</td><td>Secondary to DM type 2</td></tr><tr><td ID="instructionpot9">Secondary hyperparathyroidism of renal origin</td><td><p>Secondary hyperparathyroidism due to history of chronic kidney disease</p><p>PTH level: 199 ([REDACTED])</p></td></tr><tr><td ID="instructionpot10">Type 2 diabetes mellitus with other skin complications</td><td>Patient with physical findings of onychomycotic toenails</td></tr><tr><td ID="instructionpot11">Long term (current) use of insulin</td><td><p>Currently on Insulin: Tresiba FlexTouch and NovoLog FlexPen</p><p>Patient was offered to have nursing assistance to educate him on proper administration of insulin for 1 month. Patient refused, requesting permanent home health for insulin administration.</p></td></tr><tr><td ID="instructionpot12">Opioid dependence, uncomplicated</td><td> Currently on Tramadol. Have advised patient on importance of decreasing frequency and/or discontinuing medication but patient refuses at this time. Will continue to actively address. </td></tr><tr><td ID="instructionpot13">Other</td><td>Patient seen and examined under direct supervision of [REDACTED].  PMP was reviewed prior to dispensing medications. </td></tr></tbody></table><span class="content_span">Pending Test</span><table width="100%" border="1"><thead><tr><th>Test Name</th><th>Order Date</th></tr></thead><tbody><tr><td ID="pendingTest1">RBS/FBS</td><td>[REDACTED]</td></tr><tr><td ID="pendingTest2">PHQ9</td><td>[REDACTED]</td></tr></tbody></table><span class="content_span">Next Appt</span><table width="100%" border="1"><thead><tr><th>Details</th></tr></thead><tbody><tr><td ID="nextAppt">Follow Up: 2 Weeks, Reason: Lab Results</td></tr></tbody></table></div><h3><a name="id12" href="#toc">Progress Notes</a></h3><div><ul><li><p>Examination</p><table width="100%" border="1"><colgroup><col width="20%"/><col width="20%"/><col width="40%"/><col width="20%"/></colgroup><thead><tr><th>Category</th><th>Sub-Category</th><th>Detail</th><th>Notes</th></tr></thead><tbody><tr><td rowspan="13">[REDACTED] General Examination</td><td>GENERAL APPEARANCE</td><td colspan="2">well developed, well nourished, in acute distress</td></tr><tr><td>HEAD</td><td colspan="2">normocephalic, atraumatic</td></tr><tr><td>EYES</td><td colspan="2">pupils equal, round, reactive to light and accommodation</td></tr><tr><td>EARS</td><td colspan="2">ear canal clear, tympanic membrane intact</td></tr><tr><td>THROAT</td><td colspan="2"/></tr><tr><td>NECK/THYROID</td><td colspan="2">neck supple, full range of motion</td></tr><tr><td>HEART</td><td colspan="2">regular rate and rhythm, S1, S2 normal, </td></tr><tr><td>LUNGS</td><td colspan="2">clear to auscultation bilaterally, no wheezing, rhonchi or rales</td></tr><tr><td>ABDOMEN</td><td colspan="2">obese, soft, nontender, nondistended, bowel sounds present, no organomegaly</td></tr><tr><td>MUSCULOSKELETAL</td><td colspan="2"/></tr><tr><td>EXTREMITIES</td><td colspan="2">1+ pitting edema, bilateral, varicose veins present</td></tr><tr><td>PERIPHERAL PULSES</td><td colspan="2">1+ dorsalis pedis</td></tr><tr><td>NEUROLOGIC</td><td colspan="2">oriented to person, place and time</td></tr></tbody></table><br/></li></ul></div><br/><br/>
</body></html>